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Lyna b s t r a c t
TIMP-1, a well-known MMP inhibitor, displays other biological activities such as cell survival, pro-
liferation and differentiation in hematopoietic cells. In this report, we investigated the role of the
Src-related kinase Lyn in TIMP-1 induced UT-7 erythroleukemic cell survival. We showed that (i)
tyrosine 507 of Lyn was dephosphorylated and Lyn kinase activity enhanced by TIMP-1, (ii) Lyn
silencing suppressed TIMP-1 anti-apoptotic activity and (iii) Lyn was activated upstream the JAK2/
PI 3-kinase/Akt pathway. Our data suggest a novel role for Lyn in erythroid cell survival.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
In bone marrow, survival, proliferation and differentiation of
hematopoietic progenitor cells are supported by cytokines and
growth factors but also depend on some microenvironmental fac-
tors among which the matrix metalloproteinases (MMPs) and their
endogenous inhibitors, the Tissue Inhibitors of Metalloproteinases
(TIMPs) [1,2,3,4]. Besides their MMP inhibitory activity, TIMPs and
particularly TIMP-1 display MMP-independent cytokine-like activ-
ities and are involved in cell growth, angiogenesis, apoptosis, and
migration [4]. In bone marrow TIMP-1 participates to hematopoie-
sis as an autocrine or a paracrine factor and regulates hematopoi-
etic stem cell cycle dynamics [4,5]. We previously reported that
human erythroleukemic UT-7 cells secrete TIMP-1 which promotes
erythroid differentiation and cell survival via the JAK2/PI-3 kinase/
Akt pathway [6,7]. The identiﬁcation of intracellular pathways acti-
vated by TIMP-1 leads us to hypothesize that TIMP-1 may induce a
signal through a membrane receptor. Such receptor has been par-
tially characterized with varying molecular characteristics and
binding partners according to cell type [8]. In human breastepithelial cells, TIMP-1 interacts with the tetraspanin receptor
CD63 and integrin b1 leading to the activation of cell survival
and apoptosis inhibition [9]. In human osteosarcoma cells, TIMP-
1 interacts with avb3 integrins and confers resistance to TNF-a-in-
duced apoptosis [10]. In UT-7 cells, we demonstrated that TIMP-1
binding to a membrane proMMP-9/CD44 complex was a prerequi-
site for TIMP-1 survival signalling [11]. CD44 is a cell surface trans-
membrane glycoprotein, widely expressed in hematopoietic cells.
CD44 ligation induces intracellular signalling through the associa-
tion of its intracellular domain with receptor-associated tyrosine
kinases such as Src-related kinases [12,13]. Some studies have sug-
gested the existence of a complex between CD44 and Lyn impact-
ing on cell migration via Akt phosphorylation [14].
Nine members compose the human Src kinase family and their
activation depends on tyrosine 527 dephosphorylation followed by
tyrosine 416 autophosphorylation [15]. Activated kinase phos-
phorylates tyrosine residues of cytoplasmic substrates among
which the PI 3-kinase [16]. Numerous studies underscored the bio-
logical importance of the Src kinase Lyn for correct erythroid devel-
opment with particular attention to erythropoietin-induced
terminal differentiation [17]. Lyn is one of the key TK that regulates
erythropoietin (Epo)-induced differentiation as well as survival
and interacts with a large number of growth factors [18]. In this re-
port, we have hypothesized that Lyn could transduce TIMP-1 sur-
vival signalling downstream the proMMP-9/CD44 complex
receptor. We showed that Lyn is activated by TIMP-1 and regulates
L. Bridoux et al. / FEBS Letters 587 (2013) 1524–1528 1525JAK2/PI 3-kinase/Akt pathway in erytholeukemic UT-7 cell
survival.
2. Materials and methods
2.1. Materials
[c-32P]ATP was from Amersham Health (Velizy, France). Human
recombinant TIMP-1 was purchased from Calbiochem (VWR, Fon-
tenay-sous-Bois, France). Puriﬁed recombinant human erythropoie-
tin (Epo) (speciﬁc activity of 5000 U/mL) and PP1were from Biomol
International (Tebu-Bio, Le Perray-en-Yvelines, France). Fetal Calf
Serum (FCS) was from Biowest (Nuaillé, France). Annexin-V-FLUOS
and propidium iodide were from Roche Molecular Biochemicals
(Meylan, France). Anti-phospho-Lyn (Tyr 507), -Lyn, -phospho-Akt
(Thr 308), -Akt, -phospho-JAK2, JAK2 antibodies (1:1000)were from
Cell Signalling Technology (Ozyme, St Quentin en Yvelines, France).
Anti-p85 antibody was from Upstate Biotechnology Inc (Millipore,
Molsheim, France). a-Minimum essential medium (a-MEM) and
Opti-MEMwere from Invitrogen (Fisher Bioblock Scientiﬁc, Illkirch,
France). SiRNA Lyn were from Santa Cruz Biotechnology (Tebu-Bio,
Le Perray-en-Yvelines, France). All other reagents were purchased
from Sigma–Aldrich (St Quentin Fallavier, France).
2.2. Cell culture and stimulation
Epo-dependent UT-7 erythroid cells were cultured in a-MEM
containing 10% (v/v) FCS, 2 mM L-glutamine and 0.5 U/mL Epo. To
study signal transduction, cells were serum- and Epo-starved by
incubation for 16 h in Iscove’s modiﬁed Dulbecco’s medium
(IMDM) supplemented with 0.2% (v/v) deionised bovine serum
albumin (BSA), 2 mM L-glutamine and 20 lg/mL human holotrans-
ferrin. Cells were then incubated in IMDM and stimulated with
5 ng/mL TIMP-1 for 5 min. In some experiments, cells were incu-
bated for 30 min or 16 h with 50 lM PP1 or 50 lM AG490 respec-
tively before stimulation.
2.3. Western blot
Following stimulation, the reaction was stopped by adding ice-
cold phosphate-buffered saline (PBS) containing 50 lM Na3VO4.
Cells were then washed with PBS containing 50 lM Na3VO4
(170 g, 10 min, 4 C) and solubilized in 85 lL Laemmli sample buf-
fer (62.5 mM Tris, 2% (w/v) sodium dodecylsulfate (SDS), 10% (v/v)
b-mercaptoethanol and 1 mM Na3VO4. Whole cell extracts were
then analysed by SDS–PAGE. Proteins were transferred to a nitro-
cellulose membrane that was blocked with Tris-buffered Saline
Tween (TBST) containing 5% (w/v) non-fat dry milk for 2 h at room
temperature. The blot was then incubated with primary antibodies
in blocking solution overnight at 4 C. After 5 washes with TBST,
the blot was incubated with horseradish peroxidase-conjugated
secondary antibodies. Immunoreactive bands were revealed with
an ECL plus chemiluminescence kit from Amersham Biosciences
by using a ChemiDoc-XRS imaging station from Biorad or exposed
to Kodak X-Omat ﬁlm. When necessary, the blot was stripped by
incubation for 30 min at 55 C in 62.5 mM Tris–HCl pH 6.7 contain-
ing 100 mM b-mercaptoethanol and 2% (w/v) SDS, then washed 5
times with TBST and treated as described above. Western blot pre-
sented are representative of at least three separate experiments.
The speciﬁc signal of b-actin was used to ensure equal loading.
2.4. Immunoprecipitation
After stimulation, cells were washed twice with PBS containing
50 lM Na3VO4 and lysed for 15 min at 4 C in 250 lL lysis buffer(10 mM Tris–HCl pH 7.4, 1% (v/v) Brij 98, 150 mM NaCl, 5 mM
EDTA, 10% (v/v) glycerol, 1 mM Na3VO4, 10 lg/mL aprotinin,
10 lg/mL leupeptin, 1 lM pepstatin, 10 lg/mL E64 and 1 mM
phenylmethylsulfonylﬂuoride (PMSF)). Insoluble material was
then removed by centrifugation (15800g, 20 min, 4C) and super-
natants were immunoprecipitated with speciﬁc antibodies as pre-
viously described [11]. Samples were analysed by SDS–PAGE and
Western blotting.
2.5. Cell transfection
UT-7 cells in exponential phase of growth were washed twice
with Opti-MEM and suspended at a ﬁnal concentration of 1  107 -
cells/mL in the same medium. Cells were then electroporated using
a Biorad Gene Pulser (280 V, 250 lF) in presence of various concen-
trations of siRNA Lyn or sncRNA and incubated in a-MEM contain-
ing 10% (v/v) FCS, 1% (v/v) L-glutamine 200 mM and 0.5 U/mL Epo
for 24 h.
2.6. Lyn kinase activity
Anti-Lyn immunoprecipitates were incubated for 15 min at
30 C in 50 lL kinase buffer (25 mM Hepes pH 7.4, 2 mM MnCl2,
10 mM MgCl2, 0.5 mM Na3VO4 and 25 mM ATP) containing 5 lCi
[c-32P] ATP and 5 lg rabbit denatured enolase as substrate. The
reaction was stopped by adding Laemmli buffer and samples were
analysed by SDS–PAGE followed by autoradiography.
2.7. PI 3-kinase activity
Anti-p85 immunoprecipitates were washed thrice with lysis
buffer then twice with kinase buffer (25 mM Hepes pH 7.4,
100 mM NaCl, 5 mM MgCl2 and 200 lM adenosine). The reaction
was initiated by adding 70 lL phosphatidylinositol (PI) and phos-
phatidylserine (2 mg/mL), 10 lCi [c-32P] ATP and 25 lM ATP and
stopped by adding 100 lL 1 M HCl after incubation for 15 min at
30 C. Phospholipids were extracted and analysed by thin layer
chromatography (TLC) as previously described [7].
2.8. Quantiﬁcation and statistical analyses
The quantiﬁcation of bands from Western blots was performed
by densitometry and subsequent analysis using Quantity One soft-
ware (Biorad). Mean values of triplicate experiments were given
with standard deviation (S.D.). The statistical signiﬁcance of the
differences was calculated using student’s t test. P values referring
to corresponding controls are indicated in the ﬁgures legend
(⁄P < 0.05, ⁄⁄P < 0.01, NS non-signiﬁcative).
3. Results and discussion
3.1. Lyn is crucial for TIMP-1 survival activity
We hypothesized that cytoplasmic TK other than JAK2 may play
critical roles in TIMP-1 erythroid cell survival signalling and we
particularly focused on Lyn, one member of the Src kinases pre-
dominantly expressed in myeloid cells. The two protein isoforms
are produced in UT-7 cells (Fig. S1). The contribution of Lyn in
TIMP-1 -induced UT-7 cell survival was ﬁrst evaluated by chemical
inhibition of Lyn with PP1, a potent and selective inhibitor of Src
kinases (Fig. 1A and B). Flow cytometry analyses (Annexin V/PI)
show that TIMP-1 has signiﬁcant survival activity in UT-7 cells in
a manner similar to Epo (82 ± 9% and 86 ± 2% viable cells respec-
tively), as we previously described [7]. PP1 (50 lM) alone is not
cytotoxic for UT-7 cells (41 ± 3% viable cells) whereas it
Fig. 1. Lyn is involved in TIMP-1-induced erythroleukemic cell survival. (A) Serum- and growth factor-deprived UT-7 cells were incubated for 24 h with either 0.5 U/mL Epo
or 5 ng/mL TIMP-1 with or without 50 lM PP1. Flow cytometric proﬁles of one representative double Annexin V/PI staining are shown. (B) The histogram represents the
means ± S.D. of viable cell percentage of three independent experiments in similar conditions as in A. (C) UT-7 cells were transfected with 100–150 nM siRNA Lyn or sncRNA
and cell extracts were analysed by Western blot with anti-Lyn antibody. (D) Serum- and Epo-deprived UT-7 cells were transfected with 150 nM siRNA Lyn or sncRNA, then
incubated for 24 h with 5 ng/mL TIMP-1 and labeled with Annexin V/PI. Cumulative ﬂow cytometric proﬁle analysis of one representative Annexin V/PI staining is shown.
Percentage of the viable (j), apoptotic ( ) or necrotic (h) UT-7 cells is represented.
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TIMP-1 (36 ± 7% viable cells compared to 82 ± 9%).
To conﬁrm these data, Lyn expression was silenced by short-
interfering RNA (siRNA). The efﬁciency of the siRNA targeting Lyn
was tested and compared to silencer negative control RNA
(sncRNA) (Fig. 1C). Lyn expression is markedly reduced in 100
and 150 nM siRNA Lyn-transfected cells. Flow cytometry analyses
of Annexin V/PI-labelled cells show that siRNA cell transfection
does not alter cell viability since the viable cell ratio remains un-
changed in sncRNA- or Lyn siRNA-transfected cells as compared
to that in non-transfected cells (Fig. 1D). TIMP-1 survival activity
is abolished in siRNA Lyn-transfected cells (51.65 ± 4.82 as com-
pared to 86.71 ± 3.51). These results conﬁrm that Lyn is required
for TIMP-1 survival effect in erythroleukemic UT-7 cells.
Numerous studies reported the importance of Lyn in signal
transduction during hematopoiesis even though the majority of
them focused on erythroid differentiation. Indeed, Lyn has been
described as playing a key role in Epo-induced maturation of nor-
mal and leukemic erythroid cells [18,19]. The role of Lyn is not re-
stricted to in vitro studies since Lyn/ mice display
extramedullary stress erythropoiesis and develop anemia [20].
Over the last few years, Src kinases have also been reported as
key regulators in apoptosis prevention and furthermore v-src
expression has been described to rescue several cell types from
apoptosis [21]. In addition, Lyn silencing induces apoptosis in pri-
mary and drug-resistant leukemia cells [22]. All these datadocument that Lyn is necessary to erythroid cell survival besides
erythroid differentiation.
3.2. Lyn is activated by TIMP-1
Lyn activation was ﬁrst examined by Lyn tyrosine 507 phos-
phorylation status (Fig. 2A). Western blot with anti-phospho-Lyn
antibodies detects p-Tyr507-Lyn (the inactivated form) in un-
treated cells and dephosphorylated Lyn (the activated form) in
TIMP-1-treated cells. Tyrosine 507 dephosphorylation is followed
by tyrosine 416 autophosphorylation leading to kinase activation.
Lyn kinase activity was thus tested by its ability to phosphorylate
enolase as exogenous substrate in vitro. As shown in Fig. 2B, the le-
vel of phosphorylated enolase is signiﬁcantly increased in TIMP-1-
stimulated cells and abolished by 50 lM PP1. These results show
that Lyn is activated in response to TIMP-1.
3.3. Lyn is activated upstream the JAK2/PI 3-kinase/Akt cell survival
pathway
Activated Src phosphorylates a number of cytoplasmic sub-
strates among which the PI 3-kinase. As we previously reported,
the PI 3-kinase/Akt pathway is activated in the TIMP-1 survival ef-
fect [7]. We thus performed PI 3-kinase in vitro assay and our re-
sults show a 10-fold increase in the phosphorylated PI (PIP) level
by TIMP-1 (Fig. 3A). 50 lM PP1 inhibits this effect by 80%. To
AB
Fig. 4. Lyn is activated upstream JAK2. Serum- and Epo-deprived UT-7 cells were
incubated for 16 h with 50lM PP1 or 50 lM AG490 and then stimulated for 5 min
with 5 ng/mL TIMP-1. (A) Whole cell extracts were analysed by immunoblotting
with anti-phospho-JAK2 (p-JAK2) antibody. Anti-JAK2 immunoblot is used as a
control and a representative western blot is shown. (B) Whole cell extracts were
analysed by immunoblotting with anti-phospho-tyr507-Lyn antibody. Anti-Lyn
immunoblot is used as a control and a representative Western blot is shown.
A
B
Fig. 2. TIMP-1 enhances Lyn kinase activity. (A) Serum- and Epo-deprived UT-7
cells were stimulated for 5 min with 5 ng/mL TIMP-1. Whole cell extracts were
analysed by Western blot with anti-phospho-tyr507-Lyn antibody. Anti-Lyn and
anti b-actin antibodies were also used as control. (B) Serum- and Epo-deprived UT-7
cells were incubated for 30 min with 50 lM PP1 then stimulated for 5 min with
5 ng/mL TIMP-1 and immunoprecipitated with anti-Lyn antibodies. The detecting
band is truly Lyn and not the anti-Lyn immunoglobulin heavy chain (Fig. S2). Lyn
kinase activity was determined by in vitro enolase phosphorylation in presence of
[c-32P] ATP.
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onine 308 phosphorylation was studied in Lyn-inhibited cells
(Fig. 3B). Lyn inhibition by either chemical blockade (Fig. 3B) or
protein silencing (Fig. 3C) completely suppresses the TIMP-1 effect
on Akt phosphorylation. These results show that Lyn is activated
upstream the PI 3-kinase.
As we previously reported, JAK2 is involved in TIMP-1 anti-
apoptotic signalling and our data show that both tyrosine kinases
Lyn and JAK2 participate to the TIMP-1 survival effect [7]. The
involvement of these kinases is in agreement with other papers
describing that, in erythroid cells, they are closely related [23].A B
C
Fig. 3. Lyn is activated upstream the PI 3-kinase/Akt signalling pathway. Serum- and Epo
stimulated 5 min with 5 ng/mL TIMP-1. (A) PI 3-kinase activity was determined by PI ph
expressed as the percentage of signal obtained with TIMP-1. (B) Whole cell extracts
immunoblot is used as a control. A representative western blot is shown. (C) Representa
cells previously transfected with 100 nM siRNA Lyn or sncRNA is shown.To elucidate the possible pairwork between JAK2 and Lyn, we stud-
ied JAK2 phosphorylation in Lyn-inhibited cells. Western blotting
with anti-phospho-JAK2 (tyrosine 1007/1008) antibodies showed
that Lyn inhibition by PP1 suppressed TIMP-1-induced JAK2 phos-
phorylation(Fig. 4A). Secondly, Lyn phosphorylation was studied in
JAK2-inhibited cells. Western blotting with anti-phospho-Lyn
(tyrosine 507) showed that JAK2 inhibition by AG490 does not im-
pact TIMP-1-induced Lyn dephosphorylation (Fig. 4B). This result
indicating that Lyn is activated upstream JAK2 raises the question
about the hypothetical association of both kinases to the TIMP-1/
proMMP-9/CD44 complex receptor [11]. First, we have hypothe-
sized that JAK2 could interact with CD44. Molecular modeling
experiments have demonstrated a possible association between
the JAK2 FERM domain and the QKKKLVING CD44 cytoplasmic tail
(Fig. S3). However, immunoprecipitation and colocalization exper-
iments by confocal microscopy have failed to support our hypoth-
esis (Fig. S4).-deprived UT-7 cells were incubated for 30 min with various PP1 concentrations and
osphorylation in presence of [c-32P] ATP. Quantiﬁcation of PI phosphorylation was
were analysed by immunoblotting with anti-phospho-Akt (p-Akt) and anti-Akt
tive western blot with anti-phospho-Akt (pAkt) antibody of whole extract of UT-7
Fig. 5. Proposed model for cell survival signalling pathway induced by TIMP-1.
TIMP-1 binds to the membrane complex receptor CD44/proMMP-9 leading to Lyn
activation by an unknown mechanism. Activated Lyn regulates phosphorylation of
JAK2 which could be bound to an unknown transmembrane protein (orange
colour). JAK2 activation regulates PI 3-kinase/Akt signalling pathway and promotes
cell survival. This model is based on all our results including supplementary data.
1528 L. Bridoux et al. / FEBS Letters 587 (2013) 1524–1528Secondly, we have hypothesized that Lyn could interact with
CD44. Indeed, Lyn interaction with CD44 leads to Akt phosphoryla-
tion in human colon cancer cells [13]. Moreover, it has been demon-
strated that a region in the interface of the transmembrane and
cytopolamic domains of CD44 could interact with src kinases [14].
Unfortunately, immunoprecipitation and colocalization experi-
ments by confocal microscopy have not validated our hypothesis
(Fig. S5).
These negative results strongly suggest that one or more other
components might relay TIMP-1 signalling pathway and that the
TIMP-1 receptor is not restricted to a binary complex composed
of CD44/proMMP-9 (Fig. 5). Numerous membrane proteins such
as LRP-1, integrins or CD63 have been described as binding
TIMP-1 and/or CD44 [9,24,25]. These transmembrane proteins
could transduce TIMP-1 signalling through Lyn and JAK2 tyrosine
kinases with subsequent activation of PI 3-kinase/Akt impacting
erythroleukemic UT-7 cell survival.
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